ERBB2 and cancer: Collectively, the proliferation ability of such tumors is so strongly dependent on HER2 that it can be considered a “HER2 addiction” [11], and this has led to the development of anti-HER2 therapies dramatically improving the treatment options for patients with HER2-positive cancers [12].